Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DR-01 in Alopecia Areata or Vitiligo
NCT06602232Phase 1Active, not recruiting
- Sponsor
- Dren Bio
- Start
- Oct 2024
- Primary completion
- May 2027
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of DR-01 in alopecia areata and Vitiligo (4 arms), sponsored by Dren Bio. Primary endpoints: Incidence and severity of adverse events as assessed by CTCAE v5.0 at 12 months, Severity of Alopecia Tool score at 24 weeks and 1 more. Started Oct 2024; status: active, not recruiting.
02
Drugs
DR-01
03
Conditions
alopecia areataVitiligo
Beyond the preview
Go deeper on NCT06602232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06602232.